Regenxbio shares are trading higher after Stifel initiated coverage on the stock with a Buy rating and announced a $35 price target.
Portfolio Pulse from Benzinga Newsdesk
Regenxbio's stock is trading higher after Stifel initiated coverage on the stock with a Buy rating and a price target of $35.
November 01, 2023 | 7:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regenxbio's stock is likely to experience a positive short-term impact due to Stifel's Buy rating and $35 price target.
Stifel's initiation of coverage with a Buy rating and a $35 price target is a strong positive signal for investors. This could lead to increased demand for the stock, driving its price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100